Cowen & Co. analyst Boris Peaker maintained a Hold rating on Ironwood Pharma (IRWD) today and set a price target of $16. The company’s shares opened today at $12.78, close to its 52-week low of $12.67.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 7.5% and a 43.2% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Currently, the analyst consensus on Ironwood Pharma is a Moderate Buy with an average price target of $17.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $21.20 and a one-year low of $12.67. Currently, Ironwood Pharma has an average volume of 1.06M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ironwood Pharmaceuticals, Inc. operates as commercial biotechnology company, which discovers, develops and commercializes differentiated medicines that improve patient’s lives. Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook, Jr. and Gina Bornino Miller on January 5, 1998 and is headquartered in Cambridge, MA.
